10-Q: CareCloud Swings to Profit, Boosts Cash Flow

Sentiment:

Quarterly Report 5 August 2025 4:31 PM

CareCloud, Inc. reported a significant turnaround in GAAP net income and cash flow for the second quarter and first half of 2025, driven by cost reductions and operational efficiencies.

Capital raiseCommon stock shareholders approved an increase in the number of authorized common shares from 35 million to 85 million in January 2025, which could facilitate future equity raises.The Board of Directors exercised its conversion rights on March 6, 2025, converting a significant portion of Series A Preferred Stock into common stock, which is a form of capital restructuring that impacts the equity base and reduces future preferred dividend obligations.

Better than expectedGAAP net income significantly improved, turning from a loss to a profit for both the three and six months ended June 30, 2025, compared to the prior year periods.Cash provided by operating activities increased substantially to $12.5 million for the six months ended June 30, 2025, from $8.3 million in the prior year.The company's cash balance more than doubled, and it eliminated borrowings on its credit facility, indicating improved liquidity and financial health.Operating expenses, particularly selling and marketing and restructuring costs, were significantly reduced, contributing to improved profitability.

Summary

CareCloud, Inc. achieved a GAAP net income of $2.9 million for Q2 2025, a substantial improvement from a $1.7 million net income in Q2 2024, and $4.9 million for H1 2025, up from $1.4 million in H1 2024.
Net income attributable to common shareholders turned positive, reaching $1.5 million ($0.04 EPS) for Q2 2025 compared to a loss of $(2.2) million ($(0.14) EPS) in Q2 2024, and $0.7 million ($0.02 EPS) for H1 2025 compared to a loss of $(3.8) million ($(0.24) EPS) in H1 2024.
Net revenue for Q2 2025 decreased by 3% to $27.4 million from $28.1 million in Q2 2024, but increased by 2% for H1 2025 to $55.0 million from $54.1 million in H1 2024.
Cash provided by operating activities significantly increased to $12.5 million for H1 2025, up from $8.3 million in H1 2024, leading to a cash balance of $10.4 million at June 30, 2025, compared to $5.1 million at December 31, 2024.
The company had no borrowings outstanding on its Silicon Valley Bank credit facility as of June 30, 2025, and reduced the credit line to $10 million at its request in October 2024.
Preferred stock dividends, which were suspended in December 2023, resumed monthly payments in February 2025, with $7.1 million in undeclared dividends in arrears as of June 30, 2025.
A significant portion of Series A Preferred Stock was converted into common stock on March 6, 2025, at a rate of 7.3358 common shares per preferred share, inclusive of accumulated and unpaid dividends, leading to the delisting of Series A Preferred Stock from Nasdaq.
Operating expenses decreased by 6% for Q2 2025 and 3% for H1 2025, primarily due to reductions in selling and marketing expenses (down 33% in Q2, 35% in H1) and restructuring costs (down 80% in Q2, 69% in H1).
The company acquired RevNu Medical Management on April 1, 2025, expanding its presence in the audiology and hearing aid billing/revenue cycle IT solutions market.
CareCloud continues to leverage its offshore operations in Pakistan and Sri Lanka, which accounted for approximately 18% of total expenses for H1 2025, providing a significant cost advantage due to lower personnel costs.

Sentiment

Score: 7

Explanation: The company demonstrated a strong turnaround in GAAP profitability and cash flow, indicating improved operational efficiency and financial health. While net revenue for the quarter saw a slight decline and non-GAAP adjusted EPS decreased, the overall trajectory towards profitability and liquidity management is positive. The strategic acquisition and cost-saving measures are encouraging, though the remaining preferred dividend arrears and potential dilution from increased authorized shares warrant continued monitoring.

Positives

GAAP Net Income significantly improved, turning from a loss to a profit for both the three and six months ended June 30, 2025, compared to the prior year periods.
GAAP Earnings Per Share (EPS) for common shareholders turned positive, reaching $0.04 for Q2 2025 and $0.02 for H1 2025, a substantial improvement from losses in the prior year.
Operating Income increased by 32% for Q2 2025 and 109% for H1 2025, demonstrating enhanced operational efficiency.
Adjusted EBITDA increased by 2% for Q2 2025 to $6.5 million and by 20% for H1 2025 to $12.1 million, indicating stronger underlying business performance.
Cash provided by operating activities rose by 50% to $12.5 million for H1 2025, significantly strengthening liquidity.
The cash balance more than doubled to $10.4 million at June 30, 2025, from $5.1 million at December 31, 2024.
The company had no borrowings outstanding on its SVB credit facility at June 30, 2025, compared to $5.0 million outstanding in the prior year, reducing interest expense.
Selling and marketing expenses decreased substantially by 33% for Q2 2025 and 35% for H1 2025, reflecting successful cost management.
Restructuring costs decreased significantly by 80% for Q2 2025 and 69% for H1 2025, indicating the nearing completion of major restructuring efforts.
The acquisition of RevNu Medical Management expands the company's service offerings and client base in the audiology and hearing aid market.
Resumption of preferred stock dividends in February 2025 signals improved financial stability and commitment to preferred shareholders.
Conversion of Series A Preferred Stock to common stock reduces future preferred dividend obligations and simplifies the capital structure.
Offshore operations continue to provide a competitive cost advantage, with personnel costs approximately 18% of comparable U.S. workers.

Negatives

Net revenue for the three months ended June 30, 2025, decreased by 3% to $27.4 million compared to $28.1 million in the same period of 2024.
Non-GAAP adjusted earnings per share decreased from $0.18 in Q2 2024 to $0.07 in Q2 2025, and from $0.20 in H1 2024 to $0.13 in H1 2025, despite improved GAAP profitability.
The Medical Practice Management segment reported an operating loss of $(76) thousand for Q2 2025 and $(378) thousand for H1 2025.
Professional services revenue decreased by $415 thousand for Q2 2025 compared to the prior year.
Medical practice management services revenue decreased by $210 thousand for Q2 2025 and $461 thousand for H1 2025.
General and administrative expenses increased by 8% for Q2 2025 and 12% for H1 2025.
Research and development expense increased by 15% for H1 2025.
The carrying amount of internally-developed capitalized software decreased due to amortization exceeding new capitalization.
Approximately $7.1 million in preferred stock dividends remain undeclared and in arrears as of June 30, 2025.

Risks

Ability to manage growth, including acquiring, partnering with, and effectively integrating acquired businesses into infrastructure and avoiding associated legal exposure and liabilities.
Ability to retain clients and revenue levels, including effectively migrating new clients and maintaining or growing revenue levels of new and existing clients.
Ability to maintain operations in Pakistan, Azad Jammu and Kashmir, and Sri Lanka (Offshore Offices) in a manner that continues to enable competitively priced products and services.
Ability to keep pace with a rapidly changing healthcare industry.
Ability to consistently achieve and maintain compliance with a myriad of federal, state, foreign, local, payor, and industry requirements, regulations, rules, laws, and contracts.
Ability to maintain and protect the privacy of confidential and protected Company, client, and patient information.
Ability to develop new technologies, upgrade and adapt legacy and acquired technologies to work with evolving industry standards and third-party software platforms and technologies, and protect and enforce intellectual property rights.
Ability to attract and retain key officers and employees, and the continued involvement of Mahmud Haq (Executive Chairman), A. Hadi Chaudhry, and Stephen Snyder (Co-Chief Executive Officers) is critical to ongoing operations and business growth.
Ability to realize the expected cost savings and benefits from restructuring activities and structural cost reductions.
Ability to comply with covenants contained in the credit agreement with Silicon Valley Bank, a division of First Citizens Bank, and other future debt facilities.
Ability to continue to pay monthly dividends to holders of Series A and Series B Preferred Stock, which were suspended in December 2023 and resumed in February 2025.
Ability to incorporate AI into products faster and more successfully than competitors, protecting the privacy of medical records, and cybersecurity threats.
Ability to compete with other companies developing products and selling services competitive with ours, who may have greater resources and name recognition.
Ability to effectively integrate, manage, and keep information systems secure and operational in the event of a cyber-attack.
Ability to respond to the uncertainty resulting from pandemics, epidemics, or other public health emergencies and their impact on operations, demand for services, and financial performance.
Ability to keep and increase market acceptance of products and services.
Changes in domestic and foreign business, market, financial, political, and legal conditions.
Cash balances at Silicon Valley Bank exceed FDIC insurance coverage limits, posing a risk in case of banking system strain.
Cash held in banks in Pakistan and Sri Lanka lacks deposit insurance coverage, exposing the company to potential losses.

Future Outlook

Management forecasts sufficient liquidity to meet obligations for the next twelve months. The company plans to continue focusing on overall profitability, expense management, and revenue growth. It anticipates being able to pass on price increases for fixed-rate contracts to customers in the event of inflation. For the year ending December 31, 2025, the company will be required to obtain an attestation from its independent registered public accounting firm regarding the effectiveness of its internal controls over financial reporting and will become an accelerated filer.

Management Comments

Our offshore operations give us a competitive advantage over many industry participants.
We are able to achieve significant cost reductions and leverage technology to reduce manual work and strategically transition a portion of the remaining manual tasks to our highly-specialized, cost-efficient team in the U.S., the Pakistan Offices and Sri Lanka.
Management developed a plan that was substantially implemented during fiscal 2023 and 2024 to improve liquidity in its operations through reductions in payroll and operating expenses.
Further cost reductions will continue throughout 2025.
Management continues to focus on the Company’s overall profitability, including managing expenses, and to the extent possible growing revenue, and expects that these efforts will continue to enhance our liquidity and financial position.
Based on management’s forecasts, the Company will have sufficient liquidity to meet its obligations as they become due for the next twelve months from the date of the financial statements issuance.
We have not been adversely affected by inflation as typically we receive a percentage of the fees our clients collect from our revenue cycle management services.
We believe that we will be able to pass on any price increases for fixed rate contracts to our customers, as the prices that we charge are not governed by long-term contracts.

Industry Context

CareCloud operates in the highly complex and regulated U.S. healthcare industry, providing technology-enabled revenue cycle management and cloud-based solutions to a wide range of healthcare providers. The company is actively integrating generative AI solutions like cirrusAI to enhance clinical decision-making, streamline workflows, and optimize revenue management. Its unique business model, leveraging a large, cost-efficient offshore workforce, positions it as a consolidator in the sector, capable of transforming distressed competitors into profitable operations. The company's focus on AI and cost efficiency aligns with broader industry trends towards digital transformation and operational optimization in healthcare.

Comparison to Industry Standards

The company's offshore workforce of approximately 3,600 team members in Pakistan and Sri Lanka operates at approximately 18% of the cost of comparably educated and skilled workers in the U.S., providing a significant cost advantage over many industry participants.
CareCloud's business model has enabled it to become a leading consolidator in its industry sector, known for acquiring and positively transforming distressed competitors into profitable operations, suggesting a strong competitive position in M&A within the healthcare IT space.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
President	NA	Former Non-Independent Director (unnamed)	2024-05-01	Transition from consulting role
Co-Chief Executive Officer	NA	Former Non-Independent Director (unnamed)	2025-01-01	Promotion from President role
Chief Decision Maker (CODM)	Chief Executive Officer (CEO) and Executive Chairman (from Jan 1, 2023 to Apr 30, 2024); President, CEO and Executive Chairman (from May 1, 2024)	Executive Chairman and two Co-Chief Executive Officers	2025-01-01	Restructuring of leadership roles

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Amendment to Preferred Stock Designations	A Certificate of Amendment to the Certificate of Designations, Preferences and Rights of 11% Series A Cumulative Redeemable Preferred Stock became effective, amending certain provisions. The dividend rate was amended from 11% to 8.75% per annum, and holders now receive similar change of control protections to Series B Preferred Stock holders.	2024-09-11	Reduced future dividend obligations on Series A Preferred Stock and aligned change of control protections across preferred stock series.
Increase in Authorized Common Shares	Common stock shareholders approved an increase in the number of authorized common shares from 35 million to 85 million.	2025-01-01	Provides flexibility for future equity issuances, potentially for acquisitions, capital raises, or stock-based compensation, but also carries potential for future dilution.
Preferred Stock Dividend Resumption and Conversion	The Board of Directors declared the resumption of suspended Preferred Stock dividends in January 2025, with monthly payments resuming in February 2025. On March 6, 2025, the Board exercised its conversion rights, converting each share of Series A Preferred Stock into 7.3358 shares of common stock, inclusive of all accumulated and unpaid dividends. This led to the delisting of Series A Preferred Stock from the Nasdaq Global Market.	2025-01-01	Improved investor confidence by resuming dividends, reduced future preferred dividend cash outflows by converting a large portion of Series A Preferred Stock, and simplified the capital structure, but increased common share count and potential dilution.
Filing Status Change	The company will become an accelerated filer for the year ending December 31, 2025.	2025-12-31	Requires more stringent reporting deadlines and potentially increased compliance costs.
Internal Control Attestation Requirement	For the year ending December 31, 2025, the company will be required to have an attestation by its independent registered public accounting firm regarding the effectiveness of its internal controls over financial reporting.	2025-12-31	Increases audit scrutiny and potential compliance costs related to internal controls.

Legal Proceedings

On December 22, 2023, an arbitrator ruled in favor of Ramapo Anesthesiologists, PC, awarding $117,000 for breach of contract against Origin Healthcare Solutions, LLC; Meridian Medical Management, Inc.; and the Company. The Company's portion of $32,000 was paid in Q1 2024.
A former customer filed a complaint in New Jersey State Court seeking approximately $750,000 in damages. The Company made an offer of judgment for $200,000 in April 2024, which was accepted and paid in July 2024.
A claim from a seller in a prior acquisition for approximately $800,000 in transition-related costs was settled for $316,000 and paid in September 2024.
A dispute with a former customer filed in Massachusetts State Court in February 2018, with an initial settlement demand over $2 million, was settled for $100,000 in December 2024 and paid in February 2025.
A dispute with a former customer filed in New York Supreme Court in January 2024, with an initial settlement demand over $2.5 million, was settled for $29,000 in March 2025 and paid in June 2025.
The company is not currently a party to any legal proceedings that management believes would individually or collectively have a material adverse effect on its business, consolidated results of operations, financial position, or cash flows.

Related Party Transactions

Sales to a physician who is the wife of the Executive Chairman totaled approximately $31,000 for Q2 2025 and $51,000 for H1 2025. The accounts receivable balance from this customer was approximately $9,000 at June 30, 2025.
The Company leases its corporate office, temporary housing, a storage facility, its backup operations center in Pakistan, and an apartment in Dubai from the Executive Chairman. Related party rent expense was approximately $71,000 for Q2 2025 and $142,000 for H1 2025.
Approximately $838,000 was spent during H1 2025 to upgrade related party leased facilities.
Security deposits related to the corporate office leases amounted to approximately $16,000 at June 30, 2025.
The Company leases two facilities for temporary housing from a management employee for approximately $6,700 per month.
A consulting agreement with an entity owned by a former non-independent director (who became Co-CEO) involved the issuance of Series B Preferred Stock and monthly payments of $25,000 for an additional Statement of Work, which was terminated in April 2024.
A consulting agreement with a Board member for investor relations services incurred expenses of approximately $3,000 for Q2 2025 and $11,000 for H1 2025, with the fee structure changing from monthly to as-needed hourly basis.
The Company has paid approximately $6,500 on behalf of talkMD Clinicians, PA, a variable interest entity formed by the Executive Chairman's wife, for income taxes, although talkMD has not yet commenced operations.

Stakeholder Impact

Shareholders: Experienced a significant turnaround in GAAP net income and EPS, but also faced dilution from the conversion of Series A Preferred Stock and a decrease in non-GAAP adjusted EPS. The resumption of preferred dividends is positive for preferred shareholders, but $7.1 million in arrears remains.
Employees: The company underwent restructuring that involved workforce reductions, but continues to leverage a large offshore workforce for cost efficiency. Management changes at the executive level impact leadership and strategic direction.
Customers: Benefit from the company's expanded service offerings through acquisitions (e.g., RevNu Medical Management) and ongoing development of AI-driven solutions aimed at improving workflows and patient care.
Creditors: The company is in compliance with all covenants of its credit facility and has no outstanding borrowings on its revolving line of credit, indicating improved creditworthiness.
Suppliers: Ongoing operational activities imply continued engagement with various suppliers for services, equipment, and facilities.

Next Steps

Continue cost reductions throughout 2025.
Renew the revolving credit line with Silicon Valley Bank, which expires in October 2025.
For the year ending December 31, 2025, the company will be required to have an attestation by its independent registered public accounting firm regarding the effectiveness of its internal controls over financial reporting.
The company will become an accelerated filer for the year ending December 31, 2025.

Key Dates

Date	Description
2018-02-01	A former customer filed a complaint against the Company in Massachusetts State Court, Essex County.
2020-01-01	talkMD Clinicians, PA, a variable interest entity formed by the Executive Chairman's wife to provide telehealth services, was established.
2022-06-01	The Company entered into a one-year consulting agreement with an entity owned and controlled by a former non-independent director.
2023-02-01	The SVB revolving line of credit was increased to $25 million and its term extended for two additional years.
2023-02-01	The consulting agreement with the former non-independent director's entity was amended and extended through December 2024.
2023-08-31	The SVB credit facility agreement was amended, temporarily increasing the interest rate and slightly reducing the minimum liquidity ratio requirement.
2023-10-01	The Company committed to restructuring activities to align resources and improve profitability in the Healthcare IT segment.
2023-12-11	The Board of Directors suspended monthly cash dividends for Series A and Series B Preferred Stock.
2023-12-22	An arbitrator rendered a decision in favor of Ramapo Anesthesiologists, PC, awarding $117,000 in mitigation-related costs.
2024-01-01	A former non-independent director received an additional 14,000 shares of Series B Preferred Stock under a consulting agreement.
2024-01-01	A dispute with a former customer regarding previous services was filed in New York Supreme Court, Onondaga County.
2024-01-09	The Company entered into a consulting agreement with a Board member for investor relations and other services.
2024-02-01	An additional Statement of Work (SOW) was added to the consulting agreement with the former non-independent director's entity, with compensation of $25,000 per month.
2024-02-12	The consulting agreement with a Board member for investor relations was amended.
2024-03-31	The temporary amendments to the SVB credit facility expired, reverting to previous terms.
2024-04-01	Interest on the SVB revolving line of credit decreased to the prime rate plus 1.5%.
2024-04-30	The consulting agreement and SOW with the former non-independent director's entity were terminated by mutual consent.
2024-05-01	The former non-independent director became President of the Company.
2024-09-01	The monthly fee for the investor relations consulting agreement was reduced to $2,000 per month.
2024-09-11	A Certificate of Amendment to the Certificate of Designations, Preferences and Rights of 11% Series A Cumulative Redeemable Preferred Stock became effective, amending certain provisions.
2024-09-12	Monthly dividends for Series A Preferred Stock were reduced to approximately $1.1 million per month due to the amendment.
2024-10-01	The SVB credit line was reduced to $10 million at the Company's request.
2024-12-01	The Compensation Committee approved the award of executive bonuses based on specified criteria.
2024-12-31	The settlement amount for the Massachusetts State Court suit ($100,000) was recorded in accrued expenses.
2025-01-01	The former non-independent director became Co-Chief Executive Officer.
2025-01-01	The Executive Chairman and the two Co-CEOs began serving as the Chief Decision Maker (CODM).
2025-01-01	The investor relations consulting agreement was reduced to an as-needed hourly basis.
2025-01-01	Common stock shareholders approved an increase in the number of authorized common shares from 35 million to 85 million.
2025-01-01	The Board of Directors declared the resumption of suspended Preferred Stock dividends, starting with two months of payments.
2025-01-30	The settlement agreement for the Massachusetts State Court suit was signed by the parties.
2025-02-01	The Company resumed monthly payment of dividends on Series A and B Preferred Stock, paying one month of dividends in arrears each month.
2025-03-01	The Company made an offer of $29,000 to settle the New York Supreme Court dispute, which was accepted.
2025-03-06	The Board of Directors elected to exercise its conversion rights for Series A Preferred Stock into common stock.
2025-04-01	The Company acquired certain assets of RevNu Medical Management under an Asset Purchase Agreement.
2025-05-01	The settlement agreement for the New York Supreme Court dispute was signed by the parties.
2025-06-30	End of the current quarterly reporting period.
2025-07-04	The One Big Beautiful Bill Act (OBBBA) was signed into law, extending key provisions of the 2017 Tax Cuts and Jobs Act.
2025-07-31	Date of common stock shares outstanding (42,322,039 shares).
2025-10-12	Maturity date of the SVB revolving line of credit.
2026-12-15	Effective date for ASU 2024-03 for annual reporting periods for public business entities.
2027-06-30	Deadline for SEC removal of related disclosure requirement from Regulation S-X or S-K for ASU 2023-06.
2027-12-15	Effective date for ASU 2024-03 for interim reporting periods for public business entities.

Recommendation

hold

CareCloud's Q2 and H1 2025 results show a strong turnaround in GAAP profitability and cash flow, indicating effective cost management and operational improvements. The elimination of credit line borrowings and the strategic acquisition of RevNu are positive developments. However, the decline in non-GAAP adjusted EPS, the slight quarterly revenue dip, and the outstanding preferred dividend arrears present a mixed financial picture. The company is also undergoing significant capital structure changes and will face increased regulatory scrutiny as an accelerated filer. While the positive trends are encouraging, the mixed performance metrics and ongoing transitions suggest a 'hold' recommendation, advising investors to monitor the company's ability to sustain profitability, manage dilution, and fully integrate its strategic initiatives before making further investment decisions.

Keywords

Healthcare IT, Revenue Cycle Management, Medical Practice Management, SaaS, Electronic Health Records, AI, Artificial Intelligence, Telehealth, Patient Experience Management, Financial Performance, SEC Filing, Quarterly Report, CCLD, Healthcare Technology, Digital Health

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.